Erika Hamilton, MD, FASCO· @ErikaHamilton9 · X·· 23 hours agoScore70
Body · original
#FOURLIGHT1 CDK4 atirmociclib
Fulv + atirmo vs TPC (fulvestrant or exe/evero) post ET+ CDK4/6 in ER+ #bcsm
PFS improved 6.6 to 9.4 mos, HR 0.60
#ESMO26 #ESMOAmbassadors @OncoAlert
**1st line trial and curative trials coming!***
284 views · 7 likes · 4 reposts · 0 replies
Conference abstracts
1842Omatched by Proffered paper 2: Breast cancer, early and advanced stage
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgSource: Erika Hamilton, MD, FASCO · x.com